News

Roswell Park Experts Host Symposium to Reconnect the “Meaning in Medicine”

Join leaders from Roswell Park Comprehensive Cancer Center, along with speakers from Levine Cancer Institute and the Jacobs School of Medicine at the State University of New York at Buffalo for a special day-long symposium, “Finding the ...

News

Could Psychedelic Drugs Relieve Cancer Pain?

Roswell Park’s Palliative Care team explores surprising new ways to tackle both the physical and psychological sources of cancer pain.

Video

Roswell Park Offers Exclusive CAR T-Cell Clinical Trial for Patients with Advanced or Metastatic Hepatoma

 A new, first-in-humans clinical trial for hepatocellular carcinoma uses an “armored” CAR T-cell therapy designed to resist the hostile tumor microenvironment found in 77% of patients with this disease.

News

Join Roswell Park Revolutionaries for Cell Therapy Symposium at ASH

Renier Brentjens, MD, PhD, and Marco Davila, MD, PhD, will host a satellite symposium during this year’s ASH meeting to discuss the evolving landscape of CAR T-cell therapy.

News

Risk vs. Benefit: Clinical Trial Aims to Identify Patients with Early-Stage NSCLC Who May Not Need Immunotherapy After Surgery

Many patients with early-stage non-small cell lung cancer (NSCLC) are treated post-surgery with the monoclonal antibody durvalumab (brand name Imfinzi) — an FDA-approved regimen.

Video

Meet the Team: Chelsea Peterson, DO

Now, as a member of the Transplant and Cellular Therapy team at Roswell Park, Chelsea Peterson, DO, is eager to see the continued evolution of cellular and CAR T-cell therapies for patients beyond just those with solid tumors.